Medtronic’s (MDT) Buy Rating Reaffirmed at TD Cowen

Medtronic (NYSE:MDT)‘s stock had its “buy” rating reiterated by stock analysts at TD Cowen in a research note issued on Wednesday, Benzinga reports. They presently have a $110.00 price objective on the medical technology company’s stock. TD Cowen’s target price would suggest a potential upside of 26.20% from the company’s previous close.

Other research analysts have also recently issued reports about the company. Wells Fargo & Company raised their price objective on Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a research note on Wednesday, September 2nd. The Goldman Sachs Group decreased their price objective on Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a report on Thursday, June 4th. Rothschild & Co Redburn lowered their target price on Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research note on Friday, June 5th. Evercore set a $105.00 price target on Medtronic in a research report on Monday, July 6th. Finally, Stifel Nicolaus raised their price target on Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a research report on Wednesday, September 2nd. Nineteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $103.92.

Medtronic Trading Down 2.6%

Shares of MDT opened at $87.16 on Wednesday. The firm has a market cap of $111.49 billion, a price-to-earnings ratio of 21.47, a PEG ratio of 2.04 and a beta of 0.56. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. Medtronic has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The firm has a 50 day moving average price of $89.91 and a 200-day moving average price of $84.79.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The company had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. During the same quarter in the prior year, the company earned $1.26 EPS. The firm’s revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, equities research analysts forecast that Medtronic will post 5.98 earnings per share for the current year.

Insider Buying and Selling

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the transaction, the executive vice president owned 42,186 shares of the company’s stock, valued at $3,950,718.90. This represents a 3.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.27% of the stock is owned by insiders.

Hedge Funds Weigh In On Medtronic

Several hedge funds have recently made changes to their positions in the business. WCM Investment Management LLC purchased a new position in Medtronic during the 1st quarter valued at $965,922,000. Capital Research Global Investors boosted its stake in shares of Medtronic by 12.6% during the 4th quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock valued at $3,321,101,000 after purchasing an additional 3,880,174 shares in the last quarter. First Eagle Investment Management LLC increased its position in shares of Medtronic by 37.2% during the second quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock valued at $1,078,321,000 after buying an additional 3,739,288 shares during the period. Cullen Capital Management LLC purchased a new position in shares of Medtronic during the second quarter valued at about $202,764,000. Finally, Arrowstreet Capital Limited Partnership raised its stake in Medtronic by 74.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,236,247 shares of the medical technology company’s stock worth $406,934,000 after buying an additional 1,805,524 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic was highlighted as a potentially inexpensive growth stock trading below $100, with the article pointing to attractive valuation, financial strength and future growth prospects. 3 Absurdly Cheap Growth Stocks That Are Trading Below $100
• Positive Sentiment: Medtronic’s medical-device business was included among historically stable dividend raisers, reinforcing the investment case based on recurring healthcare demand and shareholder distributions. Historically Stable Dividend Raisers in Medical Devices
• Positive Sentiment: Options activity was notably bullish in volume terms, with investors purchasing 29,587 call options—well above the typical volume cited in the report. However, options activity reflects positioning and is not a guarantee of future stock performance.
• Neutral Sentiment: Analyst coverage offered insights on Medtronic alongside another healthcare company, but the provided report details do not specify a material rating change or new price target. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Medtronic was listed among medical stocks that could potentially beat upcoming earnings estimates, but the article is focused on screening methodology rather than a confirmed forecast for Medtronic. Medical Stocks That Could Beat Earnings
• Negative Sentiment: The main market update reported that Medtronic fell more than the overall market, indicating near-term selling pressure. The report provides performance context but no specific operational problem or negative earnings revision. Medtronic Registers a Bigger Fall Than the Market

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.